Latest Content

The resubmission follows a successful appeal by the company with the Office of New Drugs (OND).

Host Hamza Shah, OD, MS, FAAO, is joined by Kaleb Abbott, OD, MS, to discuss eye care terminology, inspired by Abbott and Pucker's paper, "It's time to retire the terms artificial tears and rewetting drops: A call for accurate terminology and updated clinical usage in eye care."

The benefits of consistent physical activity have been demonstrated for a host of systemic conditions.

Kevin J. Kovach, MD, and Giannie Castellanos, OD, gave their insights this season on what helps build referral trust and long-lasting comanagement relationships.

The next-generation FSYX ocular pressure adjusting pump adds wireless connectivity to transmit patient usage data to prescribing practices.

Healthy adults showed stable tear and meibum lipid composition from morning to evening in a prospective lipidomic study.

The FDA's OND found substantial evidence of effectiveness for bevacizumab-vikg in nAMD, clearing the way for a BLA resubmission in June 2026 and a decision expected within 60 days.

The study, led by researchers at Keio University School of Medicine, measured near add power in 6258 patients aged 40 to 79.

Upsher-Smith launched generic cyclosporine ophthalmic emulsion 0.05% in the US for tear production in inflammatory dry eye.

For Erin Tomiyama, OD, PhD, FAAO, managing myopia in pediatric patients involves decisions that extend well beyond updating a glasses prescription.

The study reviewed 1440 peer-reviewed journal articles indexed in the Web of Science Core Collection between 2010 and 2025.

Rethinking the optometrist’s role in healthy aging.

The device, described in a new study, uses a technique called temporal interference-based transcorneal electrical stimulation, or TI-TES.